Supira Medical announced today that it completed an oversubscribed Series E financing round, bringing in $120 million. The clinical-stage Shifamed portfolio company also recently completed enrollment for its U.S. SUPPORT I Early Feasibility Study (EFS) evaluating its percutaneous ventricular assist device (pVAD) for treating high-risk … [Read more...] about Supira Medical closes $120M Series E, completes enrollment in ventricular assist device study
Supira Medical
Supira begins early feasability study for percutaneous ventricular assist device
Supira Medical announced today that it began patient enrollment in a U.S. early feasibility trial of its percutaneous ventricular assist device (pVAD). The Shifamed portfolio company plans to evaluate the pVAD in patients undergoing high-risk percutaneous coronary intervention (HRPCI). Los Gatos, California-based Supira’s study looks at the … [Read more...] about Supira begins early feasability study for percutaneous ventricular assist device
